近日，在位于花都区花东镇的华润国际医药供应链（广东）项目建设现场，记者看到工程车辆往来穿 梭，施工井然有序推进。随着项目正式破土动工，一座面向粤港澳大湾区、辐射全国的现代化医药健康 物流枢纽正从蓝图加速迈向现实。 项目建设现场。 "项目以'智能运营、多元兼容、低碳示范'为核心，致力于成为粤港澳大湾区医药健康产业供应链的关 键节点。"该项目相关负责人表示，通过自动化、智能化系统的深度应用，预计可提升仓储分拣效率约 40%，同时项目将全力打造"近零碳示范园区"，践行绿色可持续发展理念。 自项目启动以来，省、市、区各级部门主动服务、精准支持，从配套路网建设、水土保持工程到审批流 程优化，提供"全方位、全天候、全流程"保障，推动项目前期手续高效办结，为工程建设按下"加速 键"。 据企业相关负责人介绍，该项目是华润医药商业服务"健康中国"战略、融入粤港澳大湾区建设的核心载 体，建成后将有效整合华南区域仓储资源，形成"1+4"全省协同网络，显著提升药品特别是急抢救药、 冷链药品的供应保障能力，同时为"港澳药械通"等跨境医药服务提供有力支撑。 该项目预计于2028年4月建成投产。届时，它不仅将大幅增强华润在华南医药物流领域 ...

Group 1 - The latest stock price of China National Pharmaceutical Group Corporation (国药一致) is 25.82 yuan, with an increase of 0.23 yuan from the previous trading day. The intraday high reached 25.87 yuan, and the low was 25.58 yuan, with a total transaction amount of 1.11 billion yuan [1] - The company operates in the pharmaceutical commercial sector and is a comprehensive pharmaceutical listed company under China National Pharmaceutical Group, with a complete industrial chain of "distribution + retail + industrial investment." Its business covers a nationwide pharmaceutical retail network and a distribution network in the Guangdong and Guangxi regions, providing supply chain services to medical institutions and retail terminals across the country [1] - According to the company's performance report, total operating revenue for the first half of 2025 was 36.797 billion yuan, a year-on-year decrease of 2.62%. The net profit attributable to the parent company was 666 million yuan, down 10.43% year-on-year. Notably, the retail segment performed well, achieving a net profit of 17 million yuan, a year-on-year increase of 215.81%, mainly due to business structure optimization and improved operational quality [1] Group 2 - On August 15, the main funds of China National Pharmaceutical Group experienced a net outflow of 18.3768 million yuan, with a cumulative net outflow of 13.3777 million yuan over the past five days [2]

Core Insights - The overall performance of the company shows a downward trend, with a revenue of 36.797 billion yuan, a year-on-year decrease of 2.62%, and a net profit of 660 million yuan, down 10.43% year-on-year but exceeding last year's total [2] - The distribution segment generated a revenue of 26.783 billion yuan, down 1.09% year-on-year, and a net profit of 482 million yuan, down 7.82% year-on-year, primarily due to industry policy changes and increased market competition [2] - The retail segment, represented by Guoyao Holdings Guoda Pharmacy, achieved a revenue of 10.479 billion yuan, down 6.46% year-on-year, but net profit increased by 215.81% to 17 million yuan [2][3] Distribution Segment Analysis - The distribution segment's revenue decline is attributed to industry policy changes and intensified market competition, leading to a slight decrease in sales revenue [2] - Increased long-term accounts receivable due to delayed payments from downstream customers resulted in higher bad debt provisions, contributing to the profit decline [2] Retail Segment Performance - Guoda Pharmacy's revenue decline is influenced by market environment, competitive landscape, and strategic store closures, but profitability improved through optimization of procurement systems and business structure [3] - The focus on enhancing store operational quality and reducing costs related to labor and rent contributed to the increase in net profit [3] - In the previous year, the retail segment reported a loss of 14 million yuan due to similar market challenges, indicating a significant recovery this year [3] Company Background - The company is part of China National Pharmaceutical Group and has a comprehensive industry chain covering distribution, retail, and industrial investment, with a nationwide retail network [4] - It collaborates closely with top global pharmaceutical and healthcare product companies, providing supply chain services to various healthcare institutions [4] Recent Market Performance - On August 15, the company's stock opened higher at 25.75 yuan, with a 0.63% increase, bringing the total market capitalization to 14.332 billion yuan [6]